Deficiencia del transportador de glucosa tipo 1 (Glut1): manifestaciones de un síndrome neurológico hereditario

Pascual, Juan M.; Lecumberri, Beatriz; Wang, Dong; Yang, Rongqian; Engelstad, Kris; Vivo, Darryl C. De

doi:10.33588/rn.3809.2003609

RevNeurol

2004

DOI: 10.33588/rn.3809.2003609

|View full text |Cite

Deficiencia del transportador de glucosa tipo 1 (Glut1): manifestaciones de un síndrome neurológico hereditario

Juan M. Pascual¹,

Beatriz Lecumberri²,

Dong Wang³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2008

2019

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Haplodeficiency of GLUT1 due to heterozygous pathogenic variants in the SLC2A1 gene, mainly of an autosomal dominant inheritance, leads to chronic hypoglycorrachia (decreased cerebrospinal fluid glucose concentration) and neurological dysfunction, which constitute the defining features of the GLUT1-DS (Pascual et al, 2007;De Vivo et al, 1991;Pascual et al, 2004). The GLUT1-DS usually presents as a classic form, with epileptic seizures (90%), but about 10% of patients are seizure-free.…”

mentioning

confidence: 99%

Glucose transporter type 1 deficiency syndrome (GLUT1-DS) – delayed diagnosis and treatment. A case report

Bogucki

Nagańska

Jurek³

et al. 2019

Journal of Epileptology

View full text Add to dashboard Cite

Background. Glucose transporter type 1 deficiency syndrome (GLUT1-DS) is a treatable metabolic disorder caused by mutation in the SLC2A1 gene. The functional deficiency of the GLUT1 protein leads to impaired glucose transport into the brain, resulting in a spectrum of neurological phenotypes. The most severe classic phenotype comprises infantile-onset epileptic encephalopathy associated with delayed development, acquired microcephaly, motor coordination disturbances, and spasticity. The less severe clinical features, such as paroxysmal exercise-induced dystonia with or without epileptic seizures, are also observed. Aim. Hypothesis, that one possible treatment option entails intrathecal injection of glucose. Material and Methods. We describe a woman, who was diagnosed as having epilepsy and treated for years with different antiepileptic drugs with no clinical effect. She had only two generalized tonic clonic seizures in her life. The patient suffered from increasing frequency of the paroxysmal involuntary movements of lower limbs, leading to gait disturbances and falls, which were misdiagnosed as epileptic seizures. The jerks of the head and limbs were observed from the first months of her life. The symptoms were provoked by stress and exertion. Additionally, mild intellectual disability was noted during her growth. Results. Glucose concentrations in cerebrospinal fluid were low. The SLC2A1 gene analysis resulted in the identification of a heterozygous missense mutation p.Arg333Trp. identification. The diagnosis of GLUT1-DS was confirmed. Conclusion. Delayed diagnosis resulted in many problems with the acceptance of the ketogenic diet, which is considered the treatment of choice in GLUT1 deficiency syndromes. To our knowledge, this is the first case report of GLUT1-DS diagnosis occurring in adulthood and published in Poland. Key words: GLUT-1 deficiency • ketogenic diet • epilepsy • dystonia BACKGROUND Glucose is the major carbon and energy source of nerve cells, supporting brain growth and neural excitation. The glucose transporter of capillary endothelial cells located at the blood brain barrier (BBB), facilitates the passive flux of glucose from blood to brain (Wong et al., 2007) and is also responsible for astrocyte glucose

show abstract

mentioning

confidence: 99%

Glucose transporter type 1 deficiency syndrome (GLUT1-DS) – delayed diagnosis and treatment. A case report

Bogucki

Nagańska

Jurek³

et al. 2019

Journal of Epileptology

View full text Add to dashboard Cite

show abstract

Deficiencia del transportador de glucosa tipo I: una enfermedad neurometabólica tratable

Gómez-Lado

Couce

Sánchez‐Salmón

et al. 2008

Anales de Pediatría

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Deficiencia del transportador de glucosa tipo 1 (Glut1): manifestaciones de un síndrome neurológico hereditario

Cited by 2 publications

References 17 publications

Glucose transporter type 1 deficiency syndrome (GLUT1-DS) – delayed diagnosis and treatment. A case report

Glucose transporter type 1 deficiency syndrome (GLUT1-DS) – delayed diagnosis and treatment. A case report

Deficiencia del transportador de glucosa tipo I: una enfermedad neurometabólica tratable

Contact Info

Product

Resources

About